FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046895044> ?p ?o ?g. }

• W2046895044 endingPage "741" @default.
• W2046895044 startingPage "735" @default.
• W2046895044 abstract "The aim of this study was to look for the maximum tolerated dose (MTD) of gemcitabine and 5-fluorouracil in a new regimen also containing the antiangiogenic bevacizumab and immunotherapy (IT) for the treatment of metastatic renal cell cancer. The primary objective of this multicenter dose-finding study was to establish the MTD of chemotherapy (CT) in combination with fixed doses of IT and bevacizumab. The secondary objective was to assess the combination's activity. Five escalated dose levels of CT with intravenous gemcitabine and 5-fluorouracil (days 1 and 8 every 28 d), were associated together with intravenous bevacizumab (10 mg/kg on days 1 and 15 every 28 d), subcutaneous interleukin-2 (1 MIU/m2 bid on days 8, 9, 15, 16, and 1 MIU/m2/d on days 10–12 and 17–19), and interferon-α-2a (3 MIU on days 10, 12, 17, 19). Of the 27 enrolled patients, 59% had been pretreated. The MTD was not reached. The highest CT dose studied was gemcitabine 1000 mg/m2 and 5-fluorouracil 600 mg/m2. More frequent grade 3 to 4 toxicities included neutropenia (63%), thrombocytopenia (33%), and fever (26%). The response rate was 33% according to the Response Evaluation Criteria in Solid Tumors. This is the first study that explored the feasibility and safety of combined bevacizumab, IT, and CT in metastatic renal cell cancer. The activity of this regimen is interesting and its efficacy warrants further trials." @default.
• W2046895044 created "2016-06-24" @default.
• W2046895044 creator A5011322435 @default.
• W2046895044 creator A5013913173 @default.
• W2046895044 creator A5021477057 @default.
• W2046895044 creator A5021963846 @default.
• W2046895044 creator A5023171492 @default.
• W2046895044 creator A5029740129 @default.
• W2046895044 creator A5041597689 @default.
• W2046895044 creator A5058550813 @default.
• W2046895044 creator A5060311012 @default.
• W2046895044 creator A5067193136 @default.
• W2046895044 creator A5069218769 @default.
• W2046895044 creator A5073892178 @default.
• W2046895044 date "2010-09-01" @default.
• W2046895044 modified "2023-10-16" @default.
• W2046895044 title "Dose-finding Trial of a Combined Regsimen With Bevacizumab, Immunotherapy, and Chemotherapy in Patients With Metastatic Renal Cell Cancer: An Italian Oncology Group for Clinical Research (GOIRC) Study" @default.
• W2046895044 cites W1572851489 @default.
• W2046895044 cites W1982320975 @default.
• W2046895044 cites W1986634084 @default.
• W2046895044 cites W1995176711 @default.
• W2046895044 cites W1999966467 @default.
• W2046895044 cites W2004869577 @default.
• W2046895044 cites W2006202974 @default.
• W2046895044 cites W2021256410 @default.
• W2046895044 cites W2046507292 @default.
• W2046895044 cites W2066604995 @default.
• W2046895044 cites W2085340970 @default.
• W2046895044 cites W2095468772 @default.
• W2046895044 cites W2100669312 @default.
• W2046895044 cites W2108499612 @default.
• W2046895044 cites W2118677643 @default.
• W2046895044 cites W2139248078 @default.
• W2046895044 cites W2141086589 @default.
• W2046895044 cites W2143782771 @default.
• W2046895044 cites W2149456801 @default.
• W2046895044 cites W2153867442 @default.
• W2046895044 cites W2153896287 @default.
• W2046895044 cites W2155012968 @default.
• W2046895044 cites W2162424705 @default.
• W2046895044 cites W2242768312 @default.
• W2046895044 cites W2270408419 @default.
• W2046895044 cites W2334694951 @default.
• W2046895044 cites W290809506 @default.
• W2046895044 doi "https://doi.org/10.1097/cji.0b013e3181eb8289" @default.
• W2046895044 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20664353" @default.
• W2046895044 hasPublicationYear "2010" @default.
• W2046895044 type Work @default.
• W2046895044 sameAs 2046895044 @default.
• W2046895044 citedByCount "10" @default.
• W2046895044 countsByYear W20468950442012 @default.
• W2046895044 countsByYear W20468950442013 @default.
• W2046895044 countsByYear W20468950442014 @default.
• W2046895044 countsByYear W20468950442015 @default.
• W2046895044 countsByYear W20468950442016 @default.
• W2046895044 countsByYear W20468950442017 @default.
• W2046895044 countsByYear W20468950442020 @default.
• W2046895044 crossrefType "journal-article" @default.
• W2046895044 hasAuthorship W2046895044A5011322435 @default.
• W2046895044 hasAuthorship W2046895044A5013913173 @default.
• W2046895044 hasAuthorship W2046895044A5021477057 @default.
• W2046895044 hasAuthorship W2046895044A5021963846 @default.
• W2046895044 hasAuthorship W2046895044A5023171492 @default.
• W2046895044 hasAuthorship W2046895044A5029740129 @default.
• W2046895044 hasAuthorship W2046895044A5041597689 @default.
• W2046895044 hasAuthorship W2046895044A5058550813 @default.
• W2046895044 hasAuthorship W2046895044A5060311012 @default.
• W2046895044 hasAuthorship W2046895044A5067193136 @default.
• W2046895044 hasAuthorship W2046895044A5069218769 @default.
• W2046895044 hasAuthorship W2046895044A5073892178 @default.
• W2046895044 hasConcept C126322002 @default.
• W2046895044 hasConcept C126894567 @default.
• W2046895044 hasConcept C141071460 @default.
• W2046895044 hasConcept C143998085 @default.
• W2046895044 hasConcept C2776694085 @default.
• W2046895044 hasConcept C2777063308 @default.
• W2046895044 hasConcept C2777802072 @default.
• W2046895044 hasConcept C2780258809 @default.
• W2046895044 hasConcept C2780456651 @default.
• W2046895044 hasConcept C2781413609 @default.
• W2046895044 hasConcept C71924100 @default.
• W2046895044 hasConcept C90924648 @default.
• W2046895044 hasConceptScore W2046895044C126322002 @default.
• W2046895044 hasConceptScore W2046895044C126894567 @default.
• W2046895044 hasConceptScore W2046895044C141071460 @default.
• W2046895044 hasConceptScore W2046895044C143998085 @default.
• W2046895044 hasConceptScore W2046895044C2776694085 @default.
• W2046895044 hasConceptScore W2046895044C2777063308 @default.
• W2046895044 hasConceptScore W2046895044C2777802072 @default.
• W2046895044 hasConceptScore W2046895044C2780258809 @default.
• W2046895044 hasConceptScore W2046895044C2780456651 @default.
• W2046895044 hasConceptScore W2046895044C2781413609 @default.
• W2046895044 hasConceptScore W2046895044C71924100 @default.
• W2046895044 hasConceptScore W2046895044C90924648 @default.
• W2046895044 hasIssue "7" @default.
• W2046895044 hasLocation W20468950441 @default.
• W2046895044 hasLocation W20468950442 @default.
• W2046895044 hasOpenAccess W2046895044 @default.

• next